Rituximab (trade names "MabThera" by Roche, "Rituxan" by Genetech) is a chimeric monoclonal antibody against the protein CD20 approved in 1997 to treat tumor. It is very effective and shows good tolerance in the treatment of Bcell lymphoma. As people understand more about Bcell and its action mechanism, it is acknowledged that besides Bcell malignancies rituximab can also treat autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus and idiopathic thrombocytopenic purpura. Global sales revenue of rituximab is USD 5,034 million, USD 6,140 million and USD 7,143 million from 2010 to 2012 respectively.

1. Investigation Report on China Rituximab
Market, 2009-2018
by
China Research and Intelligence
Explore all reports for “Life Sciences”
market
@
http://www.chinamarketresearchreports.com/cat/li
fe-sciences.html.
© ChinaMarketResearchReports.com ;
sales@chinamarketresearchreports.com ;
+1 888 391 5441

2. Investigation Report on China Rituximab
Market, 2009-2018
Rituximab (trade names "MabThera" by Roche, "Rituxan" by Genetech) is a
chimeric monoclonal antibody against the protein CD20 approved in 1997 to
treat tumor. It is very effective and shows good tolerance in the treatment of
Bcell lymphoma. As people understand more about Bcell and its action
mechanism, it is acknowledged that besides Bcell malignancies rituximab can
also treat autoimmune diseases such as rheumatoid arthritis, systemic lupus
erythematosus and idiopathic thrombocytopenic purpura. Global sales revenue
of rituximab is USD 5,034 million, USD 6,140 million and USD 7,143 million from
2010 to 2012 respectively.
Statistics shows that incidence of nonHodgkin lymphomas in China has
increased steeply from 20/1,000,000 at the end of the 20th century to
70/1,000,000 at present. Autoimmune diseases can harm central nervous
system and organs such as lung, liver and kidney, leading to organ dysfunction
and even organ failure. All of them can be lifethreatening. Statistics shows that
there are approximately 30 to 40 million people suffering from autoimmune
diseases in China. Such high incidence should be taken seriously by the public.
Inquire for a discount on this report @
http://www.chinamarketresearchreports.com/contacts/inquiry.php?name=114
© ChinaMarketResearchReports.com ;
727 .
sales@chinamarketresearchreports.com ;
+1 888 391 5441

3. Investigation Report on China Rituximab
Market, 2009-2018
By the first quarter of 2014, there were no products from local manufacturers
on the market, which was completely occupied by Roche. Early 2014,
monoclonal antibody drug "recombinant humanmouse chimeric antiCD20
monoclonal antibody injection" produced by Hisun was approved clinical. It is a
generic drug of Roche's monoclonal antibody "Rituximab". Five manufacturers
in China have reported clinical use of rituximab generic drug. It is estimated that
more generic drugs will go on the market in the next few years. According to
CRI's investigation on certain sample hospitals in China, the CAGR of sales value
of rituximab surpassed 35% from 2005 to 2012. Rituximab is expected to have
huge room to grow in future Chinese market.
Through this report, the readers can acquire the following information:
Market Share of Major Rituximab Manufacturers in China Sample Hospitals
Sales Price of Rituximab in China Hospital Market
Market Share of Rituximab by Dosage Form in China Hospital Market
Incidence of Autoimmune Diseases in China
Manufacturing Schedule of Rituximab Generic Drug
Prospect of China Rituximab Market
Complete report available @
http://www.chinamarketresearchreports.com/114727.html .
© ChinaMarketResearchReports.com ;
sales@chinamarketresearchreports.com ;
+1 888 391 5441